Kennedy Capital Management LLC Has $2.25 Million Stock Holdings in Bioventus Inc. (NYSE:BVS)

Kennedy Capital Management LLC grew its position in Bioventus Inc. (NYSE:BVS - Free Report) by 80.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 213,984 shares of the company's stock after acquiring an additional 95,266 shares during the quarter. Kennedy Capital Management LLC owned approximately 0.26% of Bioventus worth $2,247,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BVS. Plato Investment Management Ltd acquired a new position in Bioventus during the 4th quarter valued at approximately $38,000. KLP Kapitalforvaltning AS bought a new position in shares of Bioventus during the fourth quarter worth about $75,000. Quantbot Technologies LP acquired a new stake in shares of Bioventus in the 4th quarter worth about $103,000. Arizona State Retirement System acquired a new stake in shares of Bioventus in the 4th quarter worth about $109,000. Finally, HighTower Advisors LLC lifted its position in Bioventus by 11.3% in the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company's stock valued at $143,000 after purchasing an additional 1,380 shares during the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Price Performance

BVS traded up $0.04 on Friday, reaching $7.82. The company had a trading volume of 323,591 shares, compared to its average volume of 445,280. The company has a market capitalization of $640.80 million, a P/E ratio of -12.82 and a beta of 0.92. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The company has a fifty day moving average of $9.29 and a 200-day moving average of $10.61. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38.

Insider Transactions at Bioventus

In other Bioventus news, CFO Mark Leonard Singleton sold 6,498 shares of Bioventus stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $66,214.62. Following the transaction, the chief financial officer now owns 118,817 shares in the company, valued at approximately $1,210,745.23. The trade was a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares in the company, valued at $1,204,233.82. The trade was a 3.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 24,208 shares of company stock valued at $226,138. Company insiders own 32.90% of the company's stock.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group restated a "buy" rating and issued a $15.00 price target on shares of Bioventus in a research note on Monday, March 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.